FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3194871617> ?p ?o ?g. }

• W3194871617 abstract "Chronic kidney disease (CKD) and cardiovascular complications are the leading causes of death in type 2 diabetes mellitus. Apart from the standard therapy, which includes angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs), lipid-lowering medication, and anti-platelet therapy, the new group of drugs termed the 'sodium-glucose co-transporter-2 (SGLT2) inhibitors' have shown promising results in managing complications arising from the cardiovascular and renal systems in diabetics. This article attempts to highlight the role and mechanism of action of this class of drugs. We reviewed 127 articles and analyses of randomized controlled trials using several drugs in the SGLT2 inhibitor family (sotagliflozin, canagliflozin, dapagliflozin, tofogliflozin) over the past five years, out of which 58 met the criteria and aim of the study. These articles were retrieved from PubMed, Google Scholar, and Medline data sources and assessed for quality using the assessment of multiple systematic reviews (AMSTAR) checklist and Cochrane risk-of-bias tool. Results from the review showed significant benefits in reducing progressive renal decline, blood pressure control, heart failure hospitalization, death from renal or cardiovascular complications, myocardial infarction, and stroke. This benefit is also seen in non-diabetic patients, hence postulating that these effects may not be solely due to glycemic control. There are several mechanisms with which it achieves this benefit with the most significant being its role on intraglomerular pressure. Other pathways include blood pressure control, natriuresis, ventricular remodeling, erythropoiesis, lipid metabolism, plasma volume, and electrolyte imbalance. It is clear that the role of SGLT2 inhibitors isn’t limited to glycemic control and they can achieve a wide array of functions by affecting different systems. More studies need to be done to completely understand this medication to improve the quality of life in diabetic and non-diabetic patients living with CKD and cardiovascular complications. The pharmacokinetics of this drug could also help set the basis for newer medications." @default.
• W3194871617 created "2021-08-30" @default.
• W3194871617 creator A5007274041 @default.
• W3194871617 creator A5038933055 @default.
• W3194871617 creator A5052442525 @default.
• W3194871617 creator A5052699499 @default.
• W3194871617 creator A5054439312 @default.
• W3194871617 creator A5075127736 @default.
• W3194871617 creator A5078832616 @default.
• W3194871617 date "2021-08-26" @default.
• W3194871617 modified "2023-10-16" @default.
• W3194871617 title "Role of Selective Sodium-Glucose Co-Transporter-2 Inhibitors in Managing Cardio-Renal Complications in Type 2 Diabetes Mellitus: Beyond Glycemic Control" @default.
• W3194871617 cites W2027991336 @default.
• W3194871617 cites W2101508556 @default.
• W3194871617 cites W2146264128 @default.
• W3194871617 cites W2424539745 @default.
• W3194871617 cites W2524330917 @default.
• W3194871617 cites W2597475213 @default.
• W3194871617 cites W2626446274 @default.
• W3194871617 cites W2772204795 @default.
• W3194871617 cites W2791162071 @default.
• W3194871617 cites W2804805813 @default.
• W3194871617 cites W2808467887 @default.
• W3194871617 cites W2885072507 @default.
• W3194871617 cites W2899764361 @default.
• W3194871617 cites W2900413769 @default.
• W3194871617 cites W2916296804 @default.
• W3194871617 cites W2949665037 @default.
• W3194871617 cites W2956311553 @default.
• W3194871617 cites W2970624317 @default.
• W3194871617 cites W2973242786 @default.
• W3194871617 cites W2989579906 @default.
• W3194871617 cites W3003318708 @default.
• W3194871617 cites W3009611719 @default.
• W3194871617 cites W3010961195 @default.
• W3194871617 cites W3020052200 @default.
• W3194871617 cites W3022616650 @default.
• W3194871617 cites W3036607068 @default.
• W3194871617 cites W3041394830 @default.
• W3194871617 cites W3042569618 @default.
• W3194871617 cites W3083887487 @default.
• W3194871617 cites W3088173406 @default.
• W3194871617 cites W3089283105 @default.
• W3194871617 cites W3093341334 @default.
• W3194871617 cites W4253320120 @default.
• W3194871617 doi "https://doi.org/10.7759/cureus.17452" @default.
• W3194871617 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8475743" @default.
• W3194871617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34603858" @default.
• W3194871617 hasPublicationYear "2021" @default.
• W3194871617 type Work @default.
• W3194871617 sameAs 3194871617 @default.
• W3194871617 citedByCount "2" @default.
• W3194871617 countsByYear W31948716172021 @default.
• W3194871617 countsByYear W31948716172022 @default.
• W3194871617 crossrefType "journal-article" @default.
• W3194871617 hasAuthorship W3194871617A5007274041 @default.
• W3194871617 hasAuthorship W3194871617A5038933055 @default.
• W3194871617 hasAuthorship W3194871617A5052442525 @default.
• W3194871617 hasAuthorship W3194871617A5052699499 @default.
• W3194871617 hasAuthorship W3194871617A5054439312 @default.
• W3194871617 hasAuthorship W3194871617A5075127736 @default.
• W3194871617 hasAuthorship W3194871617A5078832616 @default.
• W3194871617 hasBestOaLocation W31948716171 @default.
• W3194871617 hasConcept C126322002 @default.
• W3194871617 hasConcept C134018914 @default.
• W3194871617 hasConcept C177713679 @default.
• W3194871617 hasConcept C2777180221 @default.
• W3194871617 hasConcept C2777422806 @default.
• W3194871617 hasConcept C2777451236 @default.
• W3194871617 hasConcept C2778198053 @default.
• W3194871617 hasConcept C2778653478 @default.
• W3194871617 hasConcept C2780473172 @default.
• W3194871617 hasConcept C500558357 @default.
• W3194871617 hasConcept C555293320 @default.
• W3194871617 hasConcept C71924100 @default.
• W3194871617 hasConcept C84393581 @default.
• W3194871617 hasConceptScore W3194871617C126322002 @default.
• W3194871617 hasConceptScore W3194871617C134018914 @default.
• W3194871617 hasConceptScore W3194871617C177713679 @default.
• W3194871617 hasConceptScore W3194871617C2777180221 @default.
• W3194871617 hasConceptScore W3194871617C2777422806 @default.
• W3194871617 hasConceptScore W3194871617C2777451236 @default.
• W3194871617 hasConceptScore W3194871617C2778198053 @default.
• W3194871617 hasConceptScore W3194871617C2778653478 @default.
• W3194871617 hasConceptScore W3194871617C2780473172 @default.
• W3194871617 hasConceptScore W3194871617C500558357 @default.
• W3194871617 hasConceptScore W3194871617C555293320 @default.
• W3194871617 hasConceptScore W3194871617C71924100 @default.
• W3194871617 hasConceptScore W3194871617C84393581 @default.
• W3194871617 hasLocation W31948716171 @default.
• W3194871617 hasLocation W31948716172 @default.
• W3194871617 hasLocation W31948716173 @default.
• W3194871617 hasOpenAccess W3194871617 @default.
• W3194871617 hasPrimaryLocation W31948716171 @default.
• W3194871617 hasRelatedWork W2330272871 @default.
• W3194871617 hasRelatedWork W2794310633 @default.
• W3194871617 hasRelatedWork W2795138301 @default.
• W3194871617 hasRelatedWork W3040668198 @default.
• W3194871617 hasRelatedWork W3109685549 @default.
• W3194871617 hasRelatedWork W3120289699 @default.

• next